Novartis investors will look beyond Tuesday’s quarterly results for indications about three major drug trial readouts due in the second half of the year, seen as vital to justifying the Swiss drugmaker’s premium valuation. Analysts say the experimental drugs – pelacarsen for cardiovascular disease, remibrutinib for multiple sclerosis, and genetic disorder drug del-desiran – could shape the Basel-headquartered firm’s growth outlook into the next decade, as looming patent expiries put drugmakers’ pipelines under increasing scrutiny. YourDailyAnalysis treats this as a case where the earnings report itself is almost secondary to the forward-looking commentary investors are really listening for.
The valuation math behind this trial dependency is explicit and comes directly from sell-side analysts modeling the downside. “At 16 times, you do need those growth levers to come through,” said Jefferies analyst Michael Leuchten, while Goldman Sachs analyst James Quigley put a specific threshold on it: “If two of those fail, that 16-times multiple looks very, very vulnerable.” The number that stands out to YourDailyAnalysis in that framing is Quigley’s explicit two-out-of-three bar – he’s not asking for a clean sweep, which means Novartis has some margin for one disappointment, but not two.
The peak sales potential riding on these three specific trials gives the valuation stakes concrete financial weight. Analysts estimate the three drugs together represent more than $10 billion in peak annual sales potential, which would balance out expected U.S. and European patent losses for top-sellers Cosentyx, used for psoriasis and arthritis, and breast-cancer therapy Kisqali around the turn of the decade, while sales of heart drug Entresto, already facing generic competition, are expected to drop by $4 billion this year alone. That $10 billion figure isn’t upside on top of a stable base, it’s specifically earmarked to offset patent-cliff losses that are already locked in and coming regardless of how the trials read out.
A recent, directly comparable failure at a rival gives this valuation risk real teeth rather than leaving it theoretical. Shares in Britain’s AstraZeneca slid earlier this month after the trial failure of a nerve disease drug to treat heart conditions, a precedent Ketan Patel, a fund manager at London-based Novartis investor Whitefriars, referenced directly: “Markets can be unforgiving in R&D…with even a small shortfall in clinical trials being punished heavily, whilst knockout results are treated with relief.” YourDailyAnalysis reads AstraZeneca’s stumble just weeks before Novartis’s own readouts as a live, recent template for exactly how harshly the market is prepared to react if any of these three trials disappoints.
The specific statistical bar for the pelacarsen trial illustrates how narrow the margin for a genuinely convincing result actually is. UBS analysts expect pelacarsen could reach statistical significance at around a 12% relative risk reduction, while clinicians may want to see 15% or more to view the result as clearly meaningful; the HORIZON study is testing whether lowering lipoprotein(a) reduces heart attack or stroke risk, and Sven Borho, managing partner at investment firm OrbiMed, called the opportunity significant precisely because “there is nothing on the market today” targeting Lp(a). That three-percentage-point gap between statistical significance and clinical meaningfulness is exactly the kind of ambiguous outcome – a technically positive trial that still disappoints doctors and payers – that could produce the worst of both worlds for Novartis’s stock reaction.
Watch Tuesday’s earnings call specifically for management’s tone on trial timing and any use of the phrase “clinically meaningful,” which Barclays analyst James Gordon flagged as the language investors will be parsing most closely for early signals. Your Daily Analysis views the UBS-flagged gap between the 12% statistical threshold and the 15% clinical-meaningfulness bar for pelacarsen as the single most consequential number in this entire story, since it’s the trial expected to read out first and the one most likely to set the market’s tone for how the other two are received.
